Pure Bioscience - Current report filing (8-K)
March 14 2008 - 6:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
March 10, 2008
Date of Report (Date of earliest event reported):
PURE
BIOSCIENCE
(Exact name of registrant as specified in charter)
|
|
|
California
(State or other jurisdiction of incorporation)
|
|
33-0530289
(IRS Employer Identification No.)
|
1725 Gillespie
Way, El Cajon, California 92020
(Address of principal executive offices)
(619) 586
8600
Registrant’s telephone number, including area code:
Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
[ ] Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure
of Directors of Principal Officers; Election of Directors; Appointment of Principal
Officers
On March 10, 2008, Gary Brownell
resigned as a director of Pure Bioscience. Mr. Brownell resigned in order to allow the
Company to meet corporate governance standards which requires that the Company have a
majority of independent directors. The Board of directors has expressed its
gratitude and appreciation for the many years of service to the Corporation by Mr.
Brownell. In addition, the Board of Directors extended the early termination of stock
options held by Mr. Brownell from three days following resignation until September 10,
2008. The agreement extending the early termination of the stock options is an exhibit to
this current report on Form 8-K.
The registrant has provided Mr.
Brownell with a copy of this current report prior to the filing thereof and informed him
that he had the opportunity to provide the registrant with correspondence stating whether
he agrees or disagrees with the disclosure contained in this current report which the
registrant would also file such correspondence as an exhibit to this current report or an
amendment thereto. The agreement extending the early termination of the stock options is
an exhibit to this current report on Form 8-K.
Item 9.01. Financial
Statements and Exhibits
|
(d)
|
The
following exhibits are filed with this report:
|
|
Exhibit
Number
|
Description
|
|
10.14
|
Addendum
to Stock Option Agreementsdated March 10, 2008
|
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.
Dated: March 14, 2008
PURE BIOSCIENCE
/s/ MICHAEL L. KRALL
Michael L. Krall, Chief
Executive Officer
PURE Bioscience (PK) (USOTC:PURE)
Historical Stock Chart
From Jun 2024 to Jul 2024
PURE Bioscience (PK) (USOTC:PURE)
Historical Stock Chart
From Jul 2023 to Jul 2024